반응식
[CH3:1][O:2][C:3]1[CH:4]=[C:5]([CH:8]=[C:9]([O:11][CH3:12])[CH:10]=1)[CH2:6][NH2:7].[CH2:13]([O:15][C:16]([C:18]1[C:19](=[O:41])[C:20]2[CH:25]=[N:24][C:23](S(C)(=O)=O)=[N:22][C:21]=2[N:30]([C:32]2[CH:33]=[C:34]3[C:38](=[CH:39][CH:40]=2)[CH2:37][CH2:36][CH2:35]3)[CH:31]=1)=[O:17])[CH3:14]>>[CH2:13]([O:15][C:16]([C:18]1[C:19](=[O:41])[C:20]2[CH:25]=[N:24][C:23]([NH:7][CH2:6][C:5]3[CH:8]=[C:9]([O:11][CH3:12])[CH:10]=[C:3]([O:2][CH3:1])[CH:4]=3)=[N:22][C:21]=2[N:30]([C:32]2[CH:33]=[C:34]3[C:38](=[CH:39][CH:40]=2)[CH2:37][CH2:36][CH2:35]3)[CH:31]=1)=[O:17])[CH3:14]참가 물질
3
실험 절차
Using the procedure outlined in Example 1 Step F, the title compound was prepared from 3,5-dimethoxybenzylamine and 8-indan-5-yl-2-methanesulfonyl-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester (10 mg, 0.02 mmol). 10 mg of 2-(3,5-Dimethoxy-benzylamino)-8-indan-5-yl-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester was obtained as a white solid. 1H NMR (400 MHz, CDCl3) δ (ppm): 9.27 (s, 1H), 8.47 (s, 1H), 7.30 (d, J=7.8 Hz, 1H), 7.19 (s, 1H), 7.09 (d, J=7.8 Hz, 1H), 6.44 (s, 1H), 6.26 (s, 2H), 5.99 (br, 1H), 4.37 (q, J=7.1 Hz, 2H), 4.28 (d, J=6.2 Hz, 2H), 3.74 (s, 6H), 2.98 (m, 4H), 2.16 (m, 2H), 1.38 (t, J=7.1 Hz, 3H).
출처 및 근거
- ORD 기록
- ord-2c8622961eb94f9ca0d59f465c4d5070
- 출처 데이터셋
- uspto-grants-2010_06
- 특허 번호
- US07728003B2
연결된 노트
불러오는 중…